GU Cancer Clinical Trials

UCI 16-19 ATLAS: A Randomized, Double-blind, Placebo-controlled Phase 3 Study of JNJ-56021927 in Subjects with High-risk, Localized or Locally Advanced Prostate Cancer Receiving Treatment with Primary Radiation Therapy (Uchio)

UCI 17-50** A Multicenter, Phase 1/1b, Open-Label, Dose-Escalation Study of ABBV-399, an Antibody Drug Conjugate, in Subjects with Advanced Solid Tumors (Ou)

UCI 16-76 Phase Ib/II Trial of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (mCRPC) (KEYNOTE-365) (Mar)

UCI 16-90 A Phase III, Multicenter, Randomized Study Of Atezolizumab (Anti-PD-L1 Antibody) In Combination With Enzalutamide Versus Enzalutamide Alone In Patients With Metastatic Castration-Resistant Prostate After Failure Of An Androgen Synthesis Inhibitor And Failure Of, Ineligibility For, Or Refusal Of A Taxane Regimen (Mar)

UCI 17-10 A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib plus Abiraterone plus Prednisone/ Prednisolone, Relative to Placebo plus Abiraterone plus Prednisone/ Prednisolone in Adult Male Patients with Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer (Mar)

UCI 17-25** A Phase 2, Open-Label, 2-Arm, Response Rate Study of Talazoparib in Men With DNA Repair Defects and Metastatic Castration-Resistant Prostate Cancer Who Previously Received Taxane-Based Chemotherapy and Progressed on at Least 1 Novel Hormonal Agent (Enzalutamide and/or Abiraterone Acetate/ Prednisone) (Uchio)

UCI 17-41** A Multi-Center, Randomized, Assessor-Blind, Controlled Trial Comparing the Occurrence of Major Adverse Cardiovascular Events (MACEs) in Patients with Prostate Cancer and Cardiovascular Disease Receiving Degarelix (GnRH Receptor Antagonist) or Leuprolide (GnRH Receptor Agonist) (Uchio)

UCI 17-86** Phase 1 Trial of Efficacy and Feasibility of Robot Assisted Salvage Pelvic Lymph Node Dissection (RS-PLND) or Robot Assisted Salvage Pelvic Mass Resection (RS-PMR) Post-Robot Assisted Radical Prostatectomy (Ahlering)

UCI 17-90** A Two-Part Phase I, Open Label, Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Pyrotinib in Patients with HER2-Positive Solid Tumors Whose Disease Progressed on Prior HER2 Targeted Therapy (Ou)

**Opening soon

For more details contact 1-877-UC-STUDY or ucstudy@uci.edu
**Opening soon**

**GU Cancer Clinical Trials**

**Epidemiologic**
- UCI 15-70 Small Nucleolar RNAs (snoRNAs) And Alternative Splicing In Castration-Resistant Prostate Cancer: A Potential Role In Regulation Of Androgen Receptor Signaling (Zi)
- "SUSPENDED" UCI 16-01 Pathway Analyses for Individualized Network Therapeutics for Cancer (PAINT Cancer) (Nelson)

**Operative or Neoadjuvant**
- UCI 06-13 Evaluation of Predictive Signatures of Prostate Cancer (Mercola)
- UCI 98-41 Outcomes and Assessment of Prostate Cancer at UCIMC (Ahlering)

**Observational**
- UCI 17-40 Precision Medicine for Early Prostate Cancer: Integrating Biological and Patient Complexity Variables to Predict Treatment Response (Uchio)

**Screening & Correlative**
- UCI 00-55 Retrospective Evaluation of Prostate Cancer Clinical and Pathological Outcomes (Ahlering)

**Prevention**
- UCI 14-65 Phase II Randomized, Placebo-Controlled Trial of PROSTVAC® (PSA-TRICOM) in Patients with Clinically Localized Prostate Cancer Undergoing Active Surveillance) (Uchio)
- UCI 14-90 Biomarkers and Clinical Parameters Associated with Gleason Score Upgrading (Mercola)
- UCI 17-93** Prostate-Specific Antigen Doubling-Time Kinetics: A Lifestyle Intervention of Exercise and Diet for Biochemical Recurrence post-Robot Assisted Radical Prostatectomy (RARP) (Ahlering)

**For more details contact**
1-877-UC-STUDY or ucstudy@uci.edu

Version 01/18
GU Cancer Clinical Trials

**Opening soon**

For more details contact 1-877-UC-STUDY or ucstudy@uci.edu

Version 01/18
GU Cancer Clinical Trials

**Opening soon**

For more details contact 1-877-UC-STUDY or ucstudy@uci.edu

**Version 01/18**

**UCI 16-68** A Phase III Randomized, Controlled Clinical Trial of Pembrolizumab with or without Platinum-Based Combination Chemotherapy versus Chemotherapy in Subjects with Advanced or Metastatic Urothelial Carcinoma (Uchio)

**UCI 15-77** A Phase II Clinical Trial to study the efficacy and safety of Pembrolizumab (MK-3475) in subjects with high risk non-muscle invasive bladder cancer (NMIBC) unresponsive to Bacillus Calmette-Guerin (BCG) therapy (Uchio)

**ECOG EAY131** Molecular Analysis for Therapy Choice (MATCH) (Bota)

**UCI 16-96** A Phase 1 Study of the Highly-selective RET Inhibitor, BLU-667, in Patients with Thyroid Cancer, Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors (Ou)

**SWOG S1609** DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (Bota)

**UCI 17-18** A Single-Arm, Open-Label, Multicenter Study of Enfortumab Vedotin (ASG-22CE) for Treatment of Patients with Locally Advanced or Metastatic Urothelial Cancer who Previously Received Immune Checkpoint Inhibitor (CPI) Therapy (Mar)

**UCI 17-42** A Randomized, Multicenter, Two-Arm, Single-Dose, Double-Blind, Placebo-CONtrolled Phase 3 Study of Intravesical Gapzola™ (Apaziquone) as a Chemotherapy Adjuvant to TransUrEtbral Resection of Bladder Tumors in Patients with Low- to Intermediate-Risk Non-Muscle Invasive Bladder Cancer (CONQUER) (Uchio)

**UCI 17-50** A Multicenter, Phase 1/1b, Open-Label, Dose-Escalation Study of ABBV-399, an Antibody Drug Conjugate, in Subjects with Advanced Solid Tumors (Ou)

**UCI 17-58** Phase 1-2 Study of the Safety, Pharmacokinetics, and Preliminary Activity of ASTX660 in Subjects with Advanced Solid Tumors and Lymphomas (Pinter-Brown)

**UCI 17-74** A Phase 3 randomized, Double-Blind Clinical Study of Pembrolizumab + Epacadostat vs Pembrolizumab + Placebo as a Treatment for Recurrent or Progressive Metastatic Urothelial Carcinoma in Patients who have Failed a First-Line Platinum-containing Chemotherapy Regimen for Advanced/Metastatic Disease (Uchio)

**UCI 17-75** A Phase 3 Randomized, Double-Blind Trial of Pembrolizumab (MK-3475) in Combination with Epacadostat (INCB024360) or Placebo in Participants with Cisplatin-ineligible Urothelial Carcinoma (KEYNOTE-672/ECHO-307) (Uchio)

**UCI 17-90** A Two-Part Phase I, Open Label, Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Pyrotinib in Patients with HER2-Positive Solid Tumors Whose Disease Progressed on Prior HER2 Targeted Therapy (Ou)

**UCI 16-17** A Phase I/II, Open Label, Safety and Efficacy Trial of Intravesical CG0070 and CTLA 4 Blockade as a Neo-Adjuvant Regimen for Muscle Invasive Bladder Cancer (”MIBC”) Patients Selected for Radical Cystectomy (Uchio)

**UCI 15-22** Electro-Phage and Colorimetric Aptamer Sensors for Clinical Staging and Monitoring of Bladder Cancer (Landman)